

August 01, 2022

To  
National Stock Exchange of India Ltd  
Plot No. C/1 'G' Block  
Bandra-Kurla Complex  
Bandra East, Mumbai 400051

Dear Sirs,

**Sub: Newspaper publication pertaining to financial results for the quarter ending June 30, 2022**

Pursuant to Regulation 52(8) read with Part B of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of newspaper publication pertaining to financial results for the quarter ending and year ending June 30, 2022. The publication was made in Business Standard, English newspaper on July 30, 2022.

Request you to kindly take the above submission on record.

Thanking you,

Yours faithfully  
For PNB MetLife India Insurance Company Limited

  
Yagya Turker  
Company Secretary  
Place: Mumbai



FIRST QUARTER RESULTS ROUND-UP

# Sun beats Street estimates, logs 43% rise in net

Robust sales across India, US ramp up profits

SOHINI DAS  
Mumbai, 29 July



India's largest drug maker Sun Pharmaceutical Industries has posted a 43 per cent rise in net profit for the first quarter of the current fiscal year, to ₹2,061 crore, beating Street estimates, riding on robust sales across India, the US and emerging markets. The firm's gross sales were up 10.1 per cent year-on-year (YoY) at ₹10,644 crore during the quarter, from ₹9,719 crore a year ago.

Excluding the exceptional items of Q1 last year, the adjusted net profit was up 4.1 per cent.

Ebitda (earnings before interest, taxes, depreciation and amortization) for the quarter came in at ₹2,884.4 crore (including other operating revenues), and at a margin of 26.8 per cent.

Sun Pharma shares soared 5.4 per cent on the BSE on Friday.

The company said excluding sales of Covid-19 products, the overall sales are up by about 14 per cent. The India formulations business was up 13 per cent on a like-to-like basis, excluding Covid-19 product sales of Q1 last year. "On a reported basis, the growth is 2.4 per cent over Q1 last year," the company said.

US formulation sales came in at \$420 million, up 10.7 per cent over Q1FY22, while emerging market formulation sales were \$245 million (12.6 per cent). Rest of world formulation sales came in at \$190 million (2.6 per cent).

Dilip Shangvi, managing director of the company, said, "For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our specialty business and all-round growth across markets."

The growth in Q1FY23 was led by the rise in Sun Pharma's specialty business. "Specialty business has grown 29 per

## SWEET PILL

Consolidated figures

	₹ cr			Change %	
	Q1FY22	Q4FY22	Q1FY23	QoQ	YoY
Net sales	9,669	9,386	10,644	13.4	10.1
Other income	153	114	2	-98.1	-98.6
PBIDT	2,343	-1,482	2,887	LTP	23.2
Net profit	1,444	-2,277	2,061	LTP	42.7

LTP: Loss to profit Source: Capitaline

cent, driven by Ilumya, Cequa, Odomzo and Winlevi. Our India business continues to grow faster than the market, leading to an increase in market share. We have been able to report healthy margins despite rising costs. We continue to focus on expanding our global specialty business, growing all our businesses and improving our market share," Shangvi said.

He added that specialty R&D constituted 21 per cent of overall R&D. There were four specialty molecules, which are in clinical trials now.

India formulation sales accounted for about 32 per cent of total consolidated sales while the US accounted for over 30 per cent. Sun Pharma improved its market share to 8.5 per cent in India as of June 2022. There were no sales of Covid-19 drugs during Q1FY23 in India.

# DLF Q1 profit up 39%

PRESS TRUST OF INDIA  
New Delhi, 29 July

Realty major DLF on Friday reported a 39 per cent increase in its consolidated net profit to ₹469.56 crore in the quarter ended June on better sales.

Its net profit stood at ₹337.16 crore in the year-ago period.

Total income rose to ₹1,516.28 crore in the first quarter of this fiscal from ₹1,242.27 crore in the corresponding period of the previous year, according to a regulatory filing.

In a statement, DLF said its sales bookings jumped two-fold to ₹2,040 crore during the April-June period of this fiscal year, compared with the year-ago period.

"Residential demand continues to exhibit sustained momentum. The high demand for

luxury homes has been a key trend that is expected to continue," the company said.

DLF also highlighted that its luxury project "The Camellias" contributed ₹352 crore to sales bookings during the quarter.

"While rising interest rates may pose some challenges, we expect this structural recovery in the residential segment to continue," DLF said.

The company would continue to bring newer offerings across multiple segments and geographies.

It would also remain committed to surplus cash generation from operations.

"We generated surplus cash of ₹421 crore during the quarter which led to further deleveraging and consequently our Net Debt at the end of quarter stood at ₹2,259 crore, one of the lowest levels," the company said.

## REALTY CHECK

DLF stock price in ₹



# Cipla posts 4% dip in profit on high-base effect

SOHINI DAS  
Mumbai, 29 July


Mumbai-based Cipla posted a profit after tax (PAT) of ₹686.4 crore for the first quarter of the 2022-23 fiscal year, down 3.96 per cent YoY while its consolidated revenues shrank 2 per cent to ₹5,375 crore.

Cipla's India business — comprising trade generics, prescription business and consumer health — posted a YoY dip of 8.4 per cent in revenues during the quarter to ₹2,483 crore. The company said this was due to normalisation in Covid-19 contribution to branded prescription business.

Adjusted for Covid-19 drugs, Cipla said its India business clocked a 9 per cent growth driven by core brands.

## STOCK UP

Price in ₹



# Ashok Leyland reports ₹68 crore profit in Q1

Ashok Leyland, the flagship company of the Hinduja Group, has posted a net profit of ₹68 crore during the first quarter of the financial year, compared to a net loss of ₹282 crore during the April to June quarter of the previous financial year, pushed by strong volume growth.

# Emami net down 7% due to high inflation

FMCG firm Emami on Friday reported 6.55 per cent decline in June quarter PAT at ₹72.69 crore. The firm had posted a PAT of ₹77.79 crore in April-June 2021-22, Emami said. "Unprecedented inflationary headwinds continued to impact the sector leading to softening of consumer sentiment," said Emami.

# Piramal Enterprises net slips 8.95% to ₹486 cr

Piramal Enterprises reported an 8.95 per cent decline in net profit to ₹485.98 crore for the first quarter ended June 30, impacted by higher expenses. The firm had posted a consolidated net profit of ₹533.79 crore in the same period last fiscal, Piramal Enterprises said.

# Torrent group rolls out succession plan; Aman Mehta joins pharma unit board

SOHINI DAS  
Mumbai, 29 July

The ₹22,500-crore Torrent group has rolled out its succession plan with Aman Mehta (pictured), son of Torrent Power and Torrent Pharma Chairman Samir Mehta, being appointed director on the board of the pharma company from August 1.

Sources say that similar succession plans are afoot at Torrent Power where the third generation from the promoter family would be inducted into the board soon.

Uttambhai Nathalal Mehta, a medical representative with Sandoz in the 1940s, started Torrent Pharma in 1959. It is now led by his two sons Sudhir and Samir Mehta. Torrent group had diversified into the power business around 1996.

Aman, an MBA from Columbia University, was already actively working with the group's power and pharma businesses.

"At Torrent Power, Aman was instrumental in bringing about a customer orientation transformation within the distribution business. He also made noteworthy contributions in enhancing efficiency in operations," an official release said.

He has been executive director at the ₹8,500-crore Torrent Pharma and heads the India business along with corporate HR. Aman's key achievement has been the successful integration post Unichem acquisition.

Torrent said that he has led several organic growth initiatives that have started delivering market share gains, with a focus on new product launches. In an interview with Business Standard last year, Aman had spoken passionately about the diabetic new chemical entity (NCE) that the company is working on.

"This would be a promising launch for us. The NCE has been developed with 10 years of research at Torrent. This would be the first NCE from Torrent Pharmaceuticals,"



## Torrent Pharma Q1 profit rises 7%

Torrent Pharma on Friday reported a 7 per cent increase in its consolidated net profit to ₹354 crore for the June 2022 quarter. The drug firm had posted a net profit of ₹330 crore in the April-June period of the last fiscal year. The net sales rose to ₹2,292 crore in the first quarter against ₹2,120 crore in the year-ago period, Torrent Pharma said.

Mehta had told Business Standard. The Torrent group had started working on succession plans sometime back, and the younger generations were being groomed in various business roles and verticals.

Last year, Aman had told Business Standard that they were still quite flexible to take up roles within the organisation. "For example, I was with Torrent Power earlier. All of us are keen on all businesses. Whatever opportunities come, we are open to rotation in the future too. For now, I am focused on the pharma business while two of my cousins Jinal and Varun are in the power business. There is also the gas segment, which is now a third business that is growing well," he had said.

**PNB MetLife India Insurance Company Limited: Newspaper Publication**  
Registration Number: 117 dated August 6, 2001 with IRDAI  
(Regulation 52 (8) read with regulation 52 (4) of the Listing Regulations)

Sr. No.	Particulars	Quarter ending 30 <sup>th</sup> June, 2022	Year ending 31 <sup>st</sup> March, 2022	Quarter ending 30 <sup>th</sup> June, 2021
1	Premium Income (Gross) [Refer note (c)]	1,43,385	7,34,826	1,10,967
2	Net Profit/ (Loss) for the Period (Before Tax, Exceptional and/or Extraordinary Items)	2,210	(7,104)	(14,531)
3	Net Profit/ (Loss) for the Period Before Tax (After Exceptional and/or Extraordinary Items) [Refer note (e)]	2,210	(7,104)	(14,531)
4	Net Profit/ (Loss) for the Period After Tax (After Exceptional and/or Extraordinary Items*)	1,953	(7,104)	(14,531)
5	Total Comprehensive Income for the Period [Comprising Profit/ (Loss) for the Period (After Tax) and Other Comprehensive Income (After Tax)]	NA	NA	NA
6	Equity Share Capital (As on Date)	2,01,288	2,01,288	2,01,288
7	Reserves (Excluding Revaluation Reserve) as shown in the Audited Balance Sheet [Refer Note (f)]	-	-	-
8	Earning Per Share (Face Value of ₹10 each) a. Basic (Not Annualized for Three Months) (In ₹) b. Diluted (Not Annualized for Three Months) (In ₹)	0.10 0.10	(0.35) (0.35)	(0.72) (0.72)
9	Debt-Equity Ratio (No. of Times)	0.29	0.30	NA
10	Debt Service Coverage Ratio (No. of Times)	3.73	(11.67)	NA
11	Interest Service Coverage Ratio (No. of Times)	3.73	(11.67)	NA

**Footnotes**

- This format is modified to reflect the terminology used in the Insurance Act IRDAI Regulations.
- The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the Stock Exchange and the Company's website 'https://www.pnbmetlife.com'.
- Premium income is gross of reinsurance and net of GST.
- Line Item No. 5 would be disclosed when Ind AS become applicable to Insurance companies.
- Net Profit/(Loss) before tax, for the period is Profit/(Loss) before tax as appearing in Profit and Loss Account (Shareholders' account).
- Reserves are excluding Revaluation reserve and fair value change account.
- \*Exceptional and/or Extraordinary items adjusted in the 'Statement of Policyholders' and Shareholders' account in accordance with Ind-AS Rules/AS Rules, whichever is applicable.
- The Company has issued and allotted 4,000 unsecured, subordinated, listed, rated, redeemable, taxable, non-convertible debentures (NCDs) in the nature of 'Subordinated Debt' in accordance with IRDAI (Other Forms of Capital) Regulations, 2015 of face value of ₹1,000 thousands (each at par) aggregating to ₹4,000,000 thousands through private placement on January 27, 2022. The NCDs are rated by CRISIL and ICRA and have been assigned rating of "CRISIL AA+/stable" and "ICRA AA+/stable" respectively.
- Debt-equity ratio is calculated as Total borrowings divided by Net worth. Net Worth = Share Capital + Free Reserves and Surplus + Credit/(Debit) Fair Value Change Account - Debt Balance in Profit and Loss Account.
- Debt service coverage ratio is calculated as Profit before interest and tax divided by interest expense together with principal repayments of long term debt during the period.
- Interest service coverage ratio is calculated as Profit before interest and tax divided by interest expense.

For and on behalf of the Board of Directors  
Ashish Kumar Srivastava  
Managing Director and CEO  
DIN No. 00355075

Place: Mumbai  
Date: 29<sup>th</sup> July, 2022

PNB MetLife India Insurance Company Limited, Registered office: Unit No. 701, 702 & 703, 7th Floor, West Wing, Raheja Towers, 26/27 M G Road, Bangalore -560001, Karnataka. IRDA of India Registration number 117 dated August 6, 2001 with IRDAI. (Regulation 52 (8) read with regulation 52 (4) of the Listing Regulations) CI No. U66010KA2001PLC028883. The marks "PNB" and "MetLife" are registered trademarks of Punjab National Bank and Metropolitan Life Insurance Company, respectively. PNB MetLife India Insurance Company Limited is a licensed user of these marks. Call us Toll-free at 1-800-425-6969, Website: www.pnbmetlife.com Email: indiaservice@pnbmetlife.co.in or write to us at 1st Floor, Techniplex-1, Techniplex Complex, Off Veer Savarkar Flyover, Goregaon (West), Mumbai - 400062. Phone: +91-22-41790000, Fax: +91-22-41790203. AD-NF/2022-23/105.

GENERATING A BRIGHTER FUTURE WITH GREEN ENERGY

Extract of the Unaudited Financial Results for the Quarter ended 30 June 2022 (₹ Crore)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 30.06.2022 (Unaudited)	Quarter ended 30.06.2021 (Unaudited)	Year ended 31.03.2022 (Audited)	Quarter ended 30.06.2022 (Unaudited)	Quarter ended 30.06.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
1	Total income from operations	38349.79	26038.51	116137.33	43177.14	29888.02	132669.28
2	Net profit before tax (before exceptional items)	5090.79	3538.76	19165.75	5427.88	3901.51	20520.91
3	Net profit before tax (after exceptional items)	5090.79	3538.76	19165.75	5427.88	3901.51	20520.91
4	Profit after tax	3676.43	3145.63	16111.42	3977.77	3443.72	16960.29
5	Profit after tax attributable to owners of the parent company				3936.82	3411.56	16675.90
6	Profit after tax attributable to non-controlling interest				40.95	32.16	284.39
7	Total comprehensive income after tax	3674.35	3152.74	16023.79	3946.12	3451.58	16873.04
8	Paid-up equity share capital (Face value of share ₹10/- each)	9696.67	9696.67	9696.67	9696.67	9696.67	9696.67
9	Other equity excluding revaluation reserve as per balance sheet	122050.59	112431.05	118354.40	129607.37	119454.75	125677.07
10	Net worth*	131073.17	121427.95	127391.38	138602.37	128400.81	134656.61
11	Paid up debt capital	175261.35	174140.86	170647.08	215575.64	210427.27	209555.26
12	Debtenture redemption reserve	5632.18	6050.68	5643.18	6422.84	6789.85	6421.72
13	Earnings per share (of ₹10/- each) - (not annualised) (including net movement in regulatory deferral account balances): Basic and Diluted (in ₹)	3.79	3.24	16.62	4.06	3.52	17.20
14	Earnings per share (of ₹10/- each) - (not annualised) (excluding net movement in regulatory deferral account balances): Basic and Diluted (in ₹)	3.88	2.43	15.26	3.98	2.67	15.66

\* Excluding Fly ash utilization reserve and items of Other comprehensive income.

**Notes:**

- The above is an extract of the detailed formats of financial results filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The full formats of the financial results of the Company are available on the investor section of our website https://www.ntpc.co.in and under Corporate Section of BSE Limited and National Stock Exchange of India Limited at https://www.bseindia.com & https://www.nseindia.com
- Previous periods figures have been reclassified wherever considered necessary.

Place: New Delhi  
Date: 29 July 2022

For and on behalf of Board of Directors of NTPC Limited  
Sd/-  
(Jaikumar Srinivasan)  
Director (Finance)  
DIN:01220828

Leading the Power Sector

Follow us on: [f /ntpc1](https://www.facebook.com/ntpc1) [t /ntpclimited](https://www.twitter.com/ntpclimited) [yt /ntpcld1](https://www.youtube.com/ntpcld1) [in /company/ntpc](https://www.linkedin.com/company/ntpc) [ig /ntpclimited](https://www.instagram.com/ntpclimited)

Regd. Office: NTPC Bhawan, Core-7, SCOPE Complex, 7 Institutional Area, Lodi Road, New Delhi-110003 CIN: L40101DL197501007966 E-mail: ntpccc@ntpc.co.in Website: www.ntpc.co.in

FIRST QUARTER RESULTS ROUND-UP

# Sun beats Street estimates, logs 43% rise in net

Robust sales across India, US ramp up profits

SOHINI DAS  
Mumbai, 29 July



India's largest drug maker Sun Pharmaceutical Industries has posted a 43 per cent rise in net profit for the first quarter of the current fiscal year, to ₹2,061 crore, beating Street estimates, riding on robust sales across India, the US and emerging markets. The firm's gross sales were up 10.1 per cent year-on-year (YoY) at ₹10,644 crore during the quarter, from ₹9,719 crore a year ago.

Excluding the exceptional items of Q1 last year, the adjusted net profit was up 4.1 per cent.

Ebitda (earnings before interest, taxes, depreciation and amortization) for the quarter came in at ₹2,884.4 crore (including other operating revenues), and at a margin of 26.8 per cent.

Sun Pharma shares soared 5.4 per cent on the BSE on Friday.

The company said excluding sales of Covid-19 products, the overall sales are up by about 14 per cent. The India formulations business was up 13 per cent on a like-to-like basis, excluding Covid-19 product sales of Q1 last year. "On a reported basis, the growth is 2.4 per cent over Q1 last year," the company said.

US formulation sales came in at \$420 million, up 10.7 per cent over Q1FY22, while emerging market formulation sales were \$245 million (12.6 per cent). Rest of world formulation sales came in at \$190 million (2.6 per cent).

Dilip Shangvi, managing director of the company, said, "For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our specialty business and all-round growth across markets."

The growth in Q1FY23 was led by the rise in Sun Pharma's specialty business. "Specialty business has grown 29 per

## SWEET PILL

Consolidated figures

	₹ cr			Change %	
	Q1FY22	Q4FY22	Q1FY23	QoQ	YoY
Net sales	9,669	9,386	10,644	13.4	10.1
Other income	153	114	2	-98.1	-98.6
PBIDT	2,343	-1,482	2,887	LTP	23.2
Net profit	1,444	-2,277	2,061	LTP	42.7

LTP: Loss to profit Source: Capitaline

cent, driven by Ilumya, Cequa, Odomzo and Winlevi. Our India business continues to grow faster than the market, leading to an increase in market share. We have been able to report healthy margins despite rising costs. We continue to focus on expanding our global specialty business, growing all our businesses and improving our market share," Shangvi said.

He added that specialty R&D constituted 21 per cent of overall R&D. There were four specialty molecules, which are in clinical trials now.

India formulation sales accounted for about 32 per cent of total consolidated sales while the US accounted for over 30 per cent. Sun Pharma improved its market share to 8.5 per cent in India as of June 2022. There were no sales of Covid-19 drugs during Q1FY23 in India.

# DLF Q1 profit up 39%

PRESS TRUST OF INDIA  
New Delhi, 29 July

Realty major DLF on Friday reported a 39 per cent increase in its consolidated net profit to ₹469.56 crore in the quarter ended June on better sales.

Its net profit stood at ₹337.16 crore in the year-ago period.

Total income rose to ₹1,516.28 crore in the first quarter of this fiscal from ₹1,242.27 crore in the corresponding period of the previous year, according to a regulatory filing.

In a statement, DLF said its sales bookings jumped two-fold to ₹2,040 crore during the April-June period of this fiscal year, compared with the year-ago period.

"Residential demand continues to exhibit sustained momentum. The high demand for

luxury homes has been a key trend that is expected to continue," the company said.

DLF also highlighted that its luxury project "The Camellias" contributed ₹352 crore to sales bookings during the quarter.

"While rising interest rates may pose some challenges, we expect this structural recovery in the residential segment to continue," DLF said.

The company would continue to bring newer offerings across multiple segments and geographies.

It would also remain committed to surplus cash generation from operations.

"We generated surplus cash of ₹421 crore during the quarter which led to further deleveraging and consequently our Net Debt at the end of quarter stood at ₹2,259 crore, one of the lowest levels," the company said.

## REALTY CHECK

DLF stock price in ₹



# Cipla posts 4% dip in profit on high-base effect

SOHINI DAS  
Mumbai, 29 July

Mumbai-based Cipla posted a profit after tax (PAT) of ₹686.4 crore for the first quarter of the 2022-23 fiscal year, down 3.96 per cent YoY while its consolidated revenues shrank 2 per cent to ₹5,375 crore.

Cipla's India business — comprising trade generics, prescription business and consumer health — posted a YoY dip of 8.4 per cent in revenues during the quarter to ₹2,483 crore. The company said this was due to normalisation in Covid-19 contribution to branded prescription business.

Adjusted for Covid-19 drugs, Cipla said its India business clocked a 9 per cent growth driven by core brands.

## STOCK UP

Price in ₹



# Ashok Leyland reports ₹68 crore profit in Q1

Ashok Leyland, the flagship company of the Hinduja Group, has posted a net profit of ₹68 crore during the first quarter of the financial year, compared to a net loss of ₹282 crore during the April to June quarter of the previous financial year, pushed by strong volume growth.

# Emami net down 7% due to high inflation

FMCG firm Emami on Friday reported 6.55 per cent decline in June quarter PAT at ₹72.69 crore. The firm had posted a PAT of ₹77.79 crore in April-June 2021-22, Emami said. "Unprecedented inflationary headwinds continued to impact the sector leading to softening of consumer sentiment," said Emami.

# Piramal Enterprises net slips 8.95% to ₹486 cr

Piramal Enterprises reported an 8.95 per cent decline in net profit to ₹485.98 crore for the first quarter ended June 30, impacted by higher expenses. The firm had posted a consolidated net profit of ₹533.79 crore in the same period last fiscal, Piramal Enterprises said.

# Torrent group rolls out succession plan; Aman Mehta joins pharma unit board

SOHINI DAS  
Mumbai, 29 July

The ₹22,500-crore Torrent group has rolled out its succession plan with Aman Mehta (pictured), son of Torrent Power and Torrent Pharma Chairman Samir Mehta, being appointed director on the board of the pharma company from August 1.

Sources say that similar succession plans are afoot at Torrent Power where the third generation from the promoter family would be inducted into the board soon.

Uttambhai Nathalal Mehta, a medical representative with Sandoz in the 1940s, started Torrent Pharma in 1959. It is now led by his two sons Sudhir and Samir Mehta. Torrent group had diversified into the power business around 1996.

Aman, an MBA from Columbia University, was already actively working with the group's power and pharma businesses.

"At Torrent Power, Aman was instrumental in bringing about a customer orientation transformation within the distribution business. He also made noteworthy contributions in enhancing efficiency in operations," an official release said.

He has been executive director at the ₹8,500-crore Torrent Pharma and heads the India business along with corporate HR. Aman's key achievement has been the successful integration post Unichem acquisition.

Torrent said that he has led several organic growth initiatives that have started delivering market share gains, with a focus on new product launches. In an interview with Business Standard last year, Aman had spoken passionately about the diabetic new chemical entity (NCE) that the company is working on.

"This would be a promising launch for us. The NCE has been developed with 10 years of research at Torrent. This would be the first NCE from Torrent Pharmaceuticals,"



## Torrent Pharma Q1 profit rises 7%

Torrent Pharma on Friday reported a 7 per cent increase in its consolidated net profit to ₹354 crore for the June 2022 quarter. The drug firm had posted a net profit of ₹330 crore in the April-June period of the last fiscal year. The net sales rose to ₹2,292 crore in the first quarter against ₹2,120 crore in the year-ago period, Torrent Pharma said.

Mehta had told Business Standard. The Torrent group had started working on succession plans sometime back, and the younger generations were being groomed in various business roles and verticals.

Last year, Aman had told Business Standard that they were still quite flexible to take up roles within the organisation. "For example, I was with Torrent Power earlier. All of us are keen on all businesses. Whatever opportunities come, we are open to rotation in the future too. For now, I am focused on the pharma business while two of my cousins Jinal and Varun are in the power business. There is also the gas segment, which is now a third business that is growing well," he had said.

**PNB MetLife India Insurance Company Limited: Newspaper Publication**  
Registration Number: 117 dated August 6, 2001 with IRDAI  
(Regulation 52 (8) read with regulation 52 (4) of the Listing Regulations)

(₹ in 'Lakhs)

Sr. No.	Particulars	Quarter ending 30 <sup>th</sup> June, 2022	Year ending 31 <sup>st</sup> March, 2022	Quarter ending 30 <sup>th</sup> June, 2021
1	Premium Income (Gross) [Refer note (c)]	1,43,385	7,34,826	1,10,967
2	Net Profit/ (Loss) for the Period (Before Tax, Exceptional and/or Extraordinary Items)	2,210	(7,104)	(14,531)
3	Net Profit/ (Loss) for the Period Before Tax (After Exceptional and/or Extraordinary Items) [Refer note (e)]	2,210	(7,104)	(14,531)
4	Net Profit/ (Loss) for the Period After Tax (After Exceptional and/or Extraordinary Items*)	1,953	(7,104)	(14,531)
5	Total Comprehensive Income for the Period [Comprising Profit/ (Loss) for the Period (After Tax) and Other Comprehensive Income (After Tax)]	NA	NA	NA
6	Equity Share Capital (As on Date)	2,01,288	2,01,288	2,01,288
7	Reserves (Excluding Revaluation Reserve) as shown in the Audited Balance Sheet [Refer Note (f)]	-	-	-
8	Earning Per Share (Face Value of ₹10 each) a. Basic (Not Annualized for Three Months) (In ₹) b. Diluted (Not Annualized for Three Months) (In ₹)	0.10 0.10	(0.35) (0.35)	(0.72) (0.72)
9	Debt-Equity Ratio (No. of Times)	0.29	0.30	NA
10	Debt Service Coverage Ratio (No. of Times)	3.73	(11.67)	NA
11	Interest Service Coverage Ratio (No. of Times)	3.73	(11.67)	NA

**Footnotes**  
a) This format is modified to reflect the terminology used in the Insurance Act IRDAI Regulations.  
b) The above is an extract of the detailed format of Quarterly/Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Annual Financial Results are available on the websites of the Stock Exchange and the Company's website 'https://www.pnbmetlife.com'.  
c) Premium income is gross of reinsurance and net of GST.  
d) Line Item No. 5 would be disclosed when Ind AS become applicable to Insurance companies.  
e) Net Profit/(Loss) before tax, for the period is Profit/(Loss) before tax as appearing in Profit and Loss Account (Shareholders' account).  
f) Reserves are excluding Revaluation reserve and fair value change account.  
g) \*Exceptional and/or Extraordinary items adjusted in the 'Statement of Policyholders' and Shareholders' account in accordance with Ind-AS Rules/AS Rules, whichever is applicable.  
h) The Company has issued and allotted 4,000 unsecured, subordinated, listed, rated, redeemable, taxable, non-convertible debentures (NCDs) in the nature of 'Subordinated Debt' in accordance with IRDAI (Other Forms of Capital) Regulations, 2015 of face value of ₹1,000 thousands (each at par) aggregating to ₹4,000,000 thousands through private placement on January 27, 2022. The NCDs are rated by CRISIL and ICRA and have been assigned rating of 'CRISIL AA+/stable' and 'ICRA AA+/stable' respectively.  
i) Debt-equity ratio is calculated as Total borrowings divided by Net worth. Net Worth = Share Capital + Free Reserves and Surplus + Credit/(Debit) Fair Value Change Account - Debt Balance in Profit and Loss Account.  
j) Debt service coverage ratio is calculated as Profit before interest and tax divided by interest expense together with principal repayments of long term debt during the period.  
k) Interest service coverage ratio is calculated as Profit before interest and tax divided by interest expense.

For and on behalf of the Board of Directors  
Ashish Kumar Srivastava  
Managing Director and CEO  
DIN No. 00355075

Place: Mumbai  
Date: 29<sup>th</sup> July, 2022

PNB MetLife India Insurance Company Limited, Registered office: Unit No. 701, 702 & 703, 7th Floor, West Wing, Raheja Towers, 26/27 M G Road, Bangalore -560001, Karnataka. IRDA of India Registration number 117 dated August 6, 2001 with IRDAI. (Regulation 52 (8) read with regulation 52 (4) of the Listing Regulations) CI No. U66010KA2001PLC028883. The marks "PNB" and "MetLife" are registered trademarks of Punjab National Bank and Metropolitan Life Insurance Company, respectively. PNB MetLife India Insurance Company Limited is a licensed user of these marks. Call us Toll-free at 1-800-425-6969, Website: www.pnbmetlife.com Email: indiaservice@pnbmetlife.co.in or write to us at 1st Floor, Techniplex-1, Techniplex Complex, Off Veer Savarkar Flyover, Goregaon (West), Mumbai - 400062. Phone: +91-22-41790000, Fax: +91-22-41790203. AD-NF/2022-23/105.

**GENERATING A BRIGHTER FUTURE WITH GREEN ENERGY**

75 Azadi Ka Amit Mahotsav

Extract of the Unaudited Financial Results for the Quarter ended 30 June 2022 (₹ Crore)

Sl. No.	Particulars	STANDALONE			CONSOLIDATED		
		Quarter ended 30.06.2022 (Unaudited)	Quarter ended 30.06.2021 (Unaudited)	Year ended 31.03.2022 (Audited)	Quarter ended 30.06.2022 (Unaudited)	Quarter ended 30.06.2021 (Unaudited)	Year ended 31.03.2022 (Audited)
1	Total income from operations	38349.79	26038.51	116137.33	43177.14	29888.02	132669.28
2	Net profit before tax (before exceptional items)	5090.79	3538.76	19165.75	5427.88	3901.51	20520.91
3	Net profit before tax (after exceptional items)	5090.79	3538.76	19165.75	5427.88	3901.51	20520.91
4	Profit after tax	3676.43	3145.63	16111.42	3977.77	3443.72	16960.29
5	Profit after tax attributable to owners of the parent company				3936.82	3411.56	16675.90
6	Profit after tax attributable to non-controlling interest				40.95	32.16	284.39
7	Total comprehensive income after tax	3674.35	3152.74	16023.79	3946.12	3451.58	16873.04
8	Paid-up equity share capital (Face value of share ₹10/- each)	9696.67	9696.67	9696.67	9696.67	9696.67	9696.67
9	Other equity excluding revaluation reserve as per balance sheet	122050.59	112431.05	118354.40	129607.37	119454.75	125677.07
10	Net worth*	131073.17	121427.95	127391.38	138602.37	128400.81	134656.61
11	Paid up debt capital	175261.35	174140.86	170647.08	215575.64	210427.27	209555.26
12	Debtenture redemption reserve	5632.18	6050.68	5643.18	6422.84	6789.85	6421.72
13	Earnings per share (of ₹10/- each) - (not annualised) (including net movement in regulatory deferral account balances): Basic and Diluted (in ₹)	3.79	3.24	16.62	4.06	3.52	17.20
14	Earnings per share (of ₹10/- each) - (not annualised) (excluding net movement in regulatory deferral account balances): Basic and Diluted (in ₹)	3.88	2.43	15.26	3.98	2.67	15.66

\* Excluding Fly ash utilization reserve and items of Other comprehensive income.

**Notes:**  
1 The above is an extract of the detailed formats of financial results filed with the Stock Exchanges under Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The full formats of the financial results of the Company are available on the investor section of our website https://www.ntpc.co.in and under Corporate Section of BSE Limited and National Stock Exchange of India Limited at https://www.bseindia.com & https://www.nseindia.com  
2 Previous periods figures have been reclassified wherever considered necessary.

Place: New Delhi  
Date: 29 July 2022

For and on behalf of Board of Directors of NTPC Limited  
Sd/-  
(Jaikumar Srinivasan)  
Director (Finance)  
DIN:01220828

**NTPC Limited**  
(A Govt. of India Enterprise)  
Leading the Power Sector

Follow us on:

Regd. Office: NTPC Bhawan, Core-7, SCOPE Complex, 7 Institutional Area, Lodi Road, New Delhi-110003 CIN: L40101DL1975GOI007966, E-mail: ntpccc@ntpc.co.in, Website: www.ntpc.co.in